Global Schizophrenia Therapeutics Market 2017-2021

Publisher Name :
Date: 26-Jul-2017
No. of pages: 81
Price : Single User: US $ 3500  US $ 2500 Corporate User: US $ 5000  US $ 4000
Inquire Before Buying
Avail $1000 Discount on this report till 31st December, 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.

The analysts forecast global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.

Covered in this report

This report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • AstraZeneca

  • Eli Lilly

  • GlaxoSmithKline

  • Johnson & Johnson


Other prominent vendors


  • Alkermes

  • Bristol-Myers Squibb


Market driver


  • Increasing expenditure on prescription drugs

  • For a full, detailed list, view our report


Market challenge


  • Technological advances in non-invasive neuromodulation devices

  • For a full, detailed list, view our report


Market trend


  • Increase in use of LAI antipsychotic drugs

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2021 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Avail $1000 Discount on this report till 31st December, 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Schizophrenia Therapeutics Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
Market outline

PART 05: Schizophrenia: Disease overview
Schizophrenia
Medical intervention for treating schizophrenia
Non-medical interventions for treating schizophrenia

PART 06: Key clinical trials

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Market segmentation based on drug-class
First-generation antipsychotic drugs
Second-generation antipsychotic drugs
Third generation antipsychotic drugs

PART 09: Geographical segmentation
Market overview based on geography
Schizophrenia therapeutics market in Americas
Schizophrenia therapeutics market in EMEA
Schizophrenia therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
Market drivers
Market challenges

PART 12: Market trends
Rising public interest toward mental health
Increase in use of LAI antipsychotic drugs
Availability of drugs with novel mechanism of action (MoA)

PART 13: Vendor landscape
Competitive landscape

PART 14: Key vendor analysis
AstraZeneca
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Other prominent vendors

PART 15: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Parts of brain affected by schizophrenia
Exhibit 02: Prevalence rate of disease
Exhibit 03: Reduction in prescription revenue over the years for antipsychotic drugs due to entry of generics
Exhibit 04: Types of antipsychotic drugs
Exhibit 05: Use of antipsychotic in schizophrenia
Exhibit 06: Symptoms of disease
Exhibit 07: Non-medical treatment interventions
Exhibit 08: Pipeline landscape based on number of molecules
Exhibit 09: Key clinical trials in global schizophrenia therapeutics market 2016
Exhibit 10: Snapshot of pipeline trends in global schizophrenia therapeutics market
Exhibit 11: Global schizophrenia therapeutics market snapshot
Exhibit 12: Global schizophrenia therapeutics market 2016-2021 ($ millions)
Exhibit 13: Global schizophrenia therapeutics market: Opportunity analysis
Exhibit 14: Five forces analysis
Exhibit 15: Market segmentation of global schizophrenia therapeutics market by drug-class
Exhibit 16: Global schizophrenia therapeutics market segmentation by drug-class
Exhibit 17: Global schizophrenia market revenue by drug-class, 2016-2021 (in $ millions)
Exhibit 18: Global schizophrenia first-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 19: Global schizophrenia second-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 20: Global schizophrenia third-generation antipsychotic drugs market revenue 2016-2021 ($ millions)
Exhibit 21: Global schizophrenia therapeutics market share by geography, 2016 and 2021
Exhibit 22: Global schizophrenia therapeutics market revenue by geography, 2016-2021 ($ millions)
Exhibit 23: Global schizophrenia therapeutics market share by geography, 2016-2021
Exhibit 24: Market scenario in Americas
Exhibit 25: Schizophrenia therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 26: Market scenario in EMEA
Exhibit 27: Schizophrenia therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 28: Market scenario in APAC
Exhibit 29: Schizophrenia therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 30: Psychotic symptoms
Exhibit 31: Competitive structure analysis of global schizophrenia drugs market 2016
Exhibit 32: AstraZeneca: Strength assessment
Exhibit 33: AstraZeneca: Strategy assessment
Exhibit 34: AstraZeneca: Opportunity assessment
Exhibit 35: AstraZeneca: Revenue garnered by SEROQUEL XR and SEROQUEL IR 2014-2015 ($ millions)
Exhibit 36: Eli Lilly: Key highlights
Exhibit 37: Eli Lilly: Strength assessment
Exhibit 38: Eli Lilly: Strategy assessment
Exhibit 39: Eli Lilly: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment

  • Global ADHD Drugs Sales Market Report 2017
    Published: 07-Dec-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the global ADHD Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of ADHD Drugs for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southea......
  • Global Escitalopram Market Professional Survey Report 2017
    Published: 29-Nov-2017        Price: US 3500 Onwards        Pages: 102
    This report studies Escitalopram in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Allergan - Lundbeck - Teva - Camber Pharmaceuticals - Zhejiang H......
  • United States Escitalopram Market Report 2017
    Published: 29-Nov-2017        Price: US 3800 Onwards        Pages: 110
    In this report, the United States Escitalopram market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Esc......
  • United States Risperidone Market Report 2017
    Published: 28-Nov-2017        Price: US 3800 Onwards        Pages: 114
    In this report, the United States Risperidone market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Risp......
  • Global Trazodone Hydrochloride (API) Market Professional Survey Report 2017
    Published: 28-Nov-2017        Price: US 3500 Onwards        Pages: 100
    This report studies Trazodone Hydrochloride (API) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Teva - Angelini - Mylan - Fermion - The Piramal......
  • Global Escitalopram Sales Market Report 2017
    Published: 24-Nov-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Escitalopram market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Escitalopram for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - S......
  • Global Risperidone Sales Market Report 2017
    Published: 23-Nov-2017        Price: US 4000 Onwards        Pages: 115
    In this report, the global Risperidone market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Risperidone for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - South......
  • United States Codeine Market Report 2017
    Published: 23-Nov-2017        Price: US 3800 Onwards        Pages: 108
    In this report, the United States Codeine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Codeine ......
  • Global ADHD Drugs Market Research Report 2017
    Published: 22-Nov-2017        Price: US 2900 Onwards        Pages: 109
    In this report, the global ADHD Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of ADHD Drugs in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs